BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 9021188)

  • 1. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.
    Franzot SP; Casadevall A
    Antimicrob Agents Chemother; 1997 Feb; 41(2):331-6. PubMed ID: 9021188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies.
    Nooney L; Matthews RC; Burnie JP
    Diagn Microbiol Infect Dis; 2005 Jan; 51(1):19-29. PubMed ID: 15629225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans.
    Del Poeta M; Cruz MC; Cardenas ME; Perfect JR; Heitman J
    Antimicrob Agents Chemother; 2000 Mar; 44(3):739-46. PubMed ID: 10681348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin.
    van Duin D; Casadevall A; Nosanchuk JD
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3394-400. PubMed ID: 12384341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans.
    Ernst EJ; Klepser ME; Pfaller MA
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1108-11. PubMed ID: 10722525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans.
    Hai TP; Van AD; Ngan NTT; Nhat LTH; Lan NPH; Vinh Chau NV; Thwaites GE; Krysan D; Day JN
    Mycoses; 2019 Sep; 62(9):818-825. PubMed ID: 31173410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans.
    Krishnarao TV; Galgiani JN
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1957-60. PubMed ID: 9303393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro.
    Martinez LR; Casadevall A
    Antimicrob Agents Chemother; 2006 Mar; 50(3):1021-33. PubMed ID: 16495265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans.
    Yang F; Gritsenko V; Lu H; Zhen C; Gao L; Berman J; Jiang YY
    Microbiol Spectr; 2021 Oct; 9(2):e0072321. PubMed ID: 34585947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods.
    Roling EE; Klepser ME; Wasson A; Lewis RE; Ernst EJ; Pfaller MA
    Diagn Microbiol Infect Dis; 2002 May; 43(1):13-7. PubMed ID: 12052624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans.
    Nguyen MH; Barchiesi F; McGough DA; Yu VL; Rinaldi MG
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1691-5. PubMed ID: 7486902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.
    Khyriem AB; Sujatha S; Parija SC
    Indian J Pathol Microbiol; 2006 Apr; 49(2):307-8. PubMed ID: 16933750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro susceptibility characteristics of Cryptococcus neoformans varieties from AIDS patients in Goiânia, Brazil.
    de F L Fernandes O; Passos XS; Souza LK; Miranda AT; Cerqueira CH; Silva Mdo R
    Mem Inst Oswaldo Cruz; 2003 Sep; 98(6):839-41. PubMed ID: 14595465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans.
    Klepser ME; Wolfe EJ; Pfaller MA
    J Antimicrob Chemother; 1998 Mar; 41(3):397-401. PubMed ID: 9578168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions between triazoles and amphotericin B against Cryptococcus neoformans.
    Barchiesi F; Schimizzi AM; Caselli F; Novelli A; Fallani S; Giannini D; Arzeni D; Di Cesare S; Di Francesco LF; Fortuna M; Giacometti A; Carle F; Mazzei T; Scalise G
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2435-41. PubMed ID: 10952592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
    Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
    Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil.
    Souza LK; Fernandes Ode F; Kobayashi CC; Passos XS; Costa CR; Lemos JA; Souza-Júnior AH; Silva Mdo R
    Rev Inst Med Trop Sao Paulo; 2005; 47(5):253-6. PubMed ID: 16302107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
    Hagen F; Hare Jensen R; Meis JF; Arendrup MC
    Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species.
    O'Shaughnessy EM; Meletiadis J; Stergiopoulou T; Demchok JP; Walsh TJ
    J Antimicrob Chemother; 2006 Dec; 58(6):1168-76. PubMed ID: 17071635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
    Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
    J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.